RhumbLine Advisers’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-77
| Closed | -$522 | – | 4274 |
|
|
2023
Q4 | $522 | Hold |
77
| – | – | ﹤0.01% | 4199 |
|
|
2023
Q3 | $707 | Sell |
77
-86
| -53% | -$790 | ﹤0.01% | 4210 |
|
|
2023
Q2 | $3.44K | Sell |
163
-1,686
| -91% | -$35.6K | ﹤0.01% | 4142 |
|
|
2023
Q1 | $50K | Buy |
1,849
+49
| +3% | +$1.33K | ﹤0.01% | 2908 |
|
|
2022
Q4 | $64K | Sell |
1,800
-12
| -0.7% | -$427 | ﹤0.01% | 2936 |
|
|
2022
Q3 | $409K | Buy |
1,812
+111
| +7% | +$25.1K | ﹤0.01% | 2590 |
|
|
2022
Q2 | $321K | Buy |
1,701
+430
| +34% | +$81.1K | ﹤0.01% | 2718 |
|
|
2022
Q1 | $316K | Sell |
1,271
-26
| -2% | -$6.46K | ﹤0.01% | 2627 |
|
|
2021
Q4 | $202K | Sell |
1,297
-21
| -2% | -$3.27K | ﹤0.01% | 2833 |
|
|
2021
Q3 | $264K | Buy |
1,318
+36
| +3% | +$7.21K | ﹤0.01% | 2819 |
|
|
2021
Q2 | $328K | Buy |
1,282
+399
| +45% | +$102K | ﹤0.01% | 2755 |
|
|
2021
Q1 | $234K | Sell |
883
-53
| -6% | -$14K | ﹤0.01% | 2787 |
|
|
2020
Q4 | $345K | Buy |
936
+115
| +14% | +$42.4K | ﹤0.01% | 2610 |
|
|
2020
Q3 | $201K | Sell |
821
-94
| -10% | -$23K | ﹤0.01% | 2688 |
|
|
2020
Q2 | $263K | Buy |
915
+174
| +23% | +$50K | ﹤0.01% | 2640 |
|
|
2020
Q1 | $151K | Sell |
741
-19
| -3% | -$3.87K | ﹤0.01% | 2673 |
|
|
2019
Q4 | $340K | Buy |
760
+41
| +6% | +$18.3K | ﹤0.01% | 2533 |
|
|
2019
Q3 | $221K | Buy |
719
+18
| +3% | +$5.53K | ﹤0.01% | 2715 |
|
|
2019
Q2 | $223K | Buy |
+701
| New | +$223K | ﹤0.01% | 2747 |
|